Stopping GLP-1 Medications Linked to Doubled Risk of Heart Attack, Stroke, or Death in Diabetes Patients

A new study published in The Lancet Regional Health Europe indicates that discontinuing GLP-1 receptor agonist medications is associated with a doubled combined risk of non-fatal heart attack, non-fatal stroke, or death from any cause in diabetes patients, compared to those who continue treatment. This translates to approximately four events per 100 people per year for those who stopped, versus two per 100 for those who continued. The risks were particularly higher for individuals with obesity.